KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
CAMBRIDGE, Mass., Oct. 25, 2013 /PRNewswire/ -- KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the launch of CancerPlexSM, a highly versatile and comprehensive gene testing panel to evaluate genetic changes in a patient's tumor to help oncologists effectively manage treatment options. CancerPlexSM was developed and validated in KEW's CLIA laboratory and can be used for examination of the genetic profile of many common cancers.
KEW Group is also developing state-of-the-art evidence-based therapeutic pathways that provide information about when it is appropriate to conduct diagnostic testing, including molecular diagnostics, and how that information can be used in clinical decision support.
"With the addition of the KEW CancerPlexSM, we are providing an important new service to community oncologists by incorporating state-of-the art genomic testing with evidence-based diagnostic and treatment pathways to benefit cancer patients," said Kathy Behrens Wilsey, CEO of KEW Group Inc. "These services are expected to provide the basis for both current and next generation cancer treatments."
KEW's CancerPlexSM assay utilizes next-generation sequencing to analyze more than 400 known cancer genes involved in cancer initiation and progression. The resulting information from this tumor mutation analysis can be used by physicians to supplement other patient-specific information and assist in the determination of treatment options.
About KEW Group Inc.
KEW Group Inc. provides multiple services to oncologists to assist in treatment decisions for cancer patients: genomic testing for patient tumor samples (KEW MDx) and providing genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways (KEW TPx). KEW MDx's CancerPlexSM test is the first of its diagnostic services designed to assist community oncologists in providing state-of-the-art genomic testing that previously has been available at large cancer treatment and academic centers. KEW is currently working with seven oncology practices in six different states to refine Therapeutic Pathways for seven types of cancer (breast, colorectal, lung, melanoma, lymphoma, thyroid and pancreatic). These seven practices all participate in a Center for Medicare and Medicaid Innovation Grant, which is developing and testing a Community Oncology Medical Home model, known as COME HOME. The grant is administered through Innovative Oncology Business Solutions, Inc., the organization that oversees and manages COME HOME. KEW's Treatment Pathways integrate newly emerging cancer genomic information that follows evidence standards essential to how and when to perform molecular tests, as well as inform care decisions.
KEW Investor Contact:
Kathy Behrens Wilsey
SOURCE KEW Group Inc.